SAN FRANCISCO — Decrease in IOP attributable to phacoemulsification “maxes out” regardless of starting baseline pressure, whereas the effect of the iStent inject continues to increase with increasing baseline pressure, Inder Paul Singh, MD, told Healio.com/OSN at the American Glaucoma Society annual meeting.
On behalf of the iStent inject pivotal trial team, Singh presented a poster highlighting the 2-year results of the prospective, randomized, controlled trial comparing phacoemulsification alone with phacoemulsification plus iStent inject (Glaukos) that was submitted to the
Uncategorized